Welcome to MyElanco Ireland!

The MyElanco Ireland website is intended for veterinary professionals and prescribers of animal health products. By continuing to MyElanco you are confirming your professional status as one of the above. 

Zenrelia™ gets nearly 50% more itchy dogs back to normal than Apoquel®1††

Proven Itch Relief

  • Zenrelia gets dogs back to normal
    Back to normal

    Zenrelia (Ilunocitinib) gets nearly 50% more itchy dogs back to normal than Apoquel (Oclacitinib)1††

  • Zenrelia once-daily tablets
    Once-daily dosing

    Simple, consistent dosing from the start2

  • Zenrelia delivers 24 hour itch relief
    Itch control

    Zenrelia delivers 24-hour itch relief 1,3

  • Zenrelia safety profile
    Safety profile

    Safety profile comparable to Apoquel1


Zenrelia’s price helps make the benefits of JAK inhibitors for long-term itch relief accessible to more dogs.

What do dog owners want?

79% of owners expect their dog to be back to normal when they treat their itch10. The reality is a little different, with only 53% of dogs treated with Apoquel getting back to normal.1,**


Zenrelia gets nearly 50% more itchy dogs back to normal vs Apoquel1††


Proportion of itchy dogs getting back to normal

Graph to show proportion of itchy dogs getting back to normal

A 'normal' itch score is considered to be comparable to that of a healthy, non-allergenic dog (PVAS <2).1

Zenrelia brand colour border
Zenrelia border

Questions?

*Referenceable claims in digital and social copy can be found on this page. Full reference list below.

†† 77% of dogs treated with Zenrelia achieved PVAS <2 by day 112 compared to 53% of dogs treated with Apoquel. A ‘normal’ itch score is considered to be comparable to that of a healthy, non-allergic dog (PVAS <2).1

‡ Based on list price of Zenrelia as of 07/25 vs other licensed JAK inhibitors for dogs.

** Proportion of dogs treated with Apoquel achieving a PVAS <2 by day 112.1

  1. Forster S et al. Vet Dermatol. 2025 Apr;36(2):165-176.
  2. Zenrelia Summary of Product Characteristics.
  3. Unpublished data: Owner Pruritus Assessment (PVAS) form.
  4. Gedon NKY, Mueller RS. Clin Transl Allergy. 2018 Oct; 8:41.
  5. Bond R et al. Vet Rec. 2007 Apr; 160:503–6.
  6. Unpublished data (107): Field Study for Control of Pruritus Associated with Allergic Dermatitis.
  7. Olivry T, Mueller RS. BMC Vet Res. 2017 Feb;13(1):51.
  8. Mueller RS et al. BMC Vet Res. 2016 Jan; 12:9.
  9. Mason K et al. Vet Dermatol. 2023 May; 34:115–24.
  10. Rybnícek J et al. Vet Dermatol. 2009 Apr; 20(2):115-22.

Connect with Elanco

PM-IE-25-0092

2025 may

© 2025 Elanco or its affiliates.